REsearching Coronary REduction by Appropriately Targeting Euglycemia ( Pilot Study):An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study

Aventis Pharma0 个研究点目标入组 500 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Both nondiabetic patients and patients with non-insulin-requiring type 2 diabetes mellitus admitted with a suspected AMI are eligible if they meet the following criteria:
•Signs or symptoms of AMI with definite ECG changes, defined as persistent ST-segment elevation (> or = than 1 mm)in two or more contiguous leads, or new left bundle branch block
•Onset of symptoms within 24 hours before hospital presentation
•Capillary blood glucose level on presentation > or = 8.0 mmol/L (144 mg/dL)

•Exclusion Criteria:
•Patient with conditions that REQUIRE the administration of insulin, including:
•Type 1 diabetes mellitus, defined by a documented history of diabetes mellitus before the age of 30
•Type 2 diabetes mellitus that was treated with insulin prior to AMI presentation
•Type 2 diabetes mellitus that is known to be very poorly controlled (e.g. admission capillary blood glucose > 16.0 mmol/L (288 mg/dL)or marked elevation in glucose for which the site investigator plans to treat with insulin therapy)
•A history of severe hypoglycemic episodes (defined as hypoglycemia with symptoms which the patient is unable to reverse without the assistance of another person) within the past two years
•Known or suspected end-stage liver disease (due to the risk of hypoglycemia in the setting of liver dysfunction and consequent impaired regulation of glucose homeostasis)
•Cardiogenic shock on admission (due to the inaccuracy of glucose meter readings)
•Documented pregnancy
•Any concomitant disease (e.g. cancer) that might limit life expectancy to less than 90 days
•Anticipated poor adherence with study treatments or an other factor that might jeopardize 90-day follow-up (e.g. no fixed address, long distance to hospital, etc.)
•Prior enrollment in this trial or current enrollment in another trial of ST-segment elevation myocardial infarction

发起方